{"id":2837,"date":"2024-06-07T21:46:15","date_gmt":"2024-06-07T21:46:15","guid":{"rendered":"https:\/\/www.saintjohnscancer.org\/blog\/?p=2837"},"modified":"2024-06-11T23:57:16","modified_gmt":"2024-06-11T23:57:16","slug":"dr-ora-gordon-spotlights-the-promise-of-mced-multi-cancer-early-detection","status":"publish","type":"post","link":"https:\/\/www.saintjohnscancer.org\/blog\/thoracic\/dr-ora-gordon-spotlights-the-promise-of-mced-multi-cancer-early-detection\/","title":{"rendered":"Dr. Ora Gordon Spotlights the Promise of MCED &#8211; Multi-Cancer Early Detection"},"content":{"rendered":"\n<h2>Identifying as many as 50 different types of cancer in a single blood test is quite remarkable.<\/h2>\n<p>In our&nbsp;<span style=\"margin: 0px;padding: 0px\">previous News post, <a href=\"https:\/\/www.saintjohnscancer.org\/about-us\/news\/news\/multi-cancer-early-detection-mced-testing-now-availabe\/\" target=\"_blank\" rel=\"noopener\"><em>Providence Offers Multi-cancer Early Detection (MCED) Testing,<\/em><\/a> we learned the scope of MCED and Providence&rsquo;s partnership with Grail and their Galleri&reg; test. <\/span>Today, Dr. Ora Gordon breaks down its simplicity, empowering individuals and their primary care providers to take advantage of this test through Providence&mdash;a large regional provider that understands how to treat the whole person.<\/p>\n<div style=\"text-align: center!important;padding-bottom: 0px;margin-top: -25px\">\n<blockquote><p><span style=\"font-size: 30px!important;line-height: 34px!important;letter-spacing: -1.5px;text-align: center\"> &ldquo;We can find cells floating in the blood with small amounts of DNA that don&rsquo;t belong to the person.&nbsp; They actually belong to the cancer, and not only can we see if there&rsquo;s cancer present but we&rsquo;re  able to detect where it comes from: the ovary, the lung, the esophagus, or the breast tissue. This is truly transformational in how we screen&nbsp;for cancers.&rdquo;<\/span><\/p><\/blockquote>\n<p style=\"text-align: right;padding-right: 5%;margin-bottom: 25px;margin-top: 0px\">&ndash; Ora Gordon, MD<\/p>\n<\/div>\n<h3>Dr. Ora Gordon Provides an MCED Overview<\/h3>\n<div style=\"margin-left:5%;margin-right:5%\"><iframe loading=\"lazy\" title=\"Ora Gordon, MD, FACMGG, explains Multi-Cancer Early Dectection (MCED) at Providence, Saint John's\" width=\"756\" height=\"425\" src=\"https:\/\/www.youtube.com\/embed\/sdRbIBu17HI?rel=0&amp;showinfo=0\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/div>\n<p style=\"text-align: center;font-size: 14px;line-height: 14px;margin-top: 15px;color: #101010;margin-bottom:60px\">Dr. Ora Gordon provides key insights for MCED at Providence.<\/p>\n<p>What Dr. Gordon indicates in the DNA process is the best part. Understanding that cancer is present before symptoms manifest is a game changer, but knowing where in the body it originates provides providers with a road map for treatment. Each cancer has a standard of care, but there is more. Cancer itself has a genetic profile, which may indicate whether alternative treatments are of more significant benefit.&nbsp; As such, some cancers of the same organ can be more or less aggressive, which defines the care approach.&nbsp; Successful treatment of the more aggressive cancers depends highly on timing, potentially treating an elusive case in stages 0-2 versus late discovery, stages 3 or 4.&nbsp; &nbsp;The later the stage, the more time cancer has had to advance into other parts of the body, which determines statistical survivability.<\/p>\n<div style=\"text-align: center!important;padding-bottom: 0px;margin-top: -25px\">\n<blockquote><p><span style=\"font-size: 30px!important;line-height: 34px!important;letter-spacing: -1.5px;text-align: center\"> &ldquo;The goal is to detect cancer early when it can be cured.&rdquo;<\/span><\/p><\/blockquote>\n<p style=\"text-align: right;padding-right: 5%;margin-bottom: 25px;margin-top: 0px\">&ndash; Ora Gordon, MD<\/p>\n<\/div>\n<p>The magic of Saint John&rsquo;s is our ability to extend care with highly experienced specialists and access to innovative treatments and clinical trials.&nbsp; If cancer cases become complex, treatment is adapted to the patient, elevating the standard of care and providing additional treatment options that are more difficult to harness elsewhere.&nbsp; Moreover, early-stage cases are met with curative effects, often requiring no additional treatment beyond surgery and radiation, or far less long-term treatment.<\/p>\n<h3>For screening and questions about MCED, please call our regional genetics scheduling line at 818-748-4748.<\/h3>\n<p>Or visit, <a href=\"https:\/\/www.providence.org\/locations\/socal\/genetics-and-genomics\" target=\"_blank\" rel=\"noopener\">Providence.org\/Locations\/SoCal\/Genetics-and-Genomics<\/a><\/p>\n<p><strong>Galleri&reg; Multi-cancer Early Detection<\/strong><\/p>\n<ol style=\"line-height:18px\">\n<li>Detects a shared cancer signal across 50+ types of cancer through a simple blood draw<\/li>\n<li>Uses machine learning and methylation pattern recognition to detect a cancer signal<\/li>\n<li>Predicts origin of the cancer signal to guide next steps to diagnosis<\/li>\n<\/ol>\n<h4>See a list of cancers discoverable with the Galleri test.<\/h4>\n<p><a href=\"https:\/\/www.saintjohnscancer.org\/about-us\/news\/news\/multi-cancer-early-detection-mced-testing-now-availabe\/\" target=\"_blank\" rel=\"noopener\"><u>Providence Offers Multi-cancer Early Detection (MCED) Testing<\/u><\/a><\/p>\n<div style=\"width:100%;height:60px\">&nbsp;<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>Identifying as many as 50 different types of cancer in a single blood test is quite remarkable. In our&nbsp;previous News&#8230;<\/p>\n","protected":false},"author":62,"featured_media":2839,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[150,149,146,161,138,199,134,139],"tags":[],"class_list":["post-2837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","category-breast","category-gastrointestinal","category-gynecologic","category-melanoma","category-ovarian","category-thoracic","category-urology"],"acf":{"doc_author":"4376","header_scripts":""},"_links":{"self":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts\/2837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/comments?post=2837"}],"version-history":[{"count":0,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/posts\/2837\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/media\/2839"}],"wp:attachment":[{"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/media?parent=2837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/categories?post=2837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/blog\/wp-json\/wp\/v2\/tags?post=2837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}